Middle East and African Insulin Infusion Pumps Market Size
| Study Period | 2018 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 40.22 Million |
| Market Size (2029) | USD 50.85 Million |
| CAGR (2024 - 2029) | 4.80 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Middle East and African Insulin Infusion Pumps Market Analysis
The Middle East and Africa Insulin Infusion Pumps Market size is estimated at USD 40.22 million in 2024, and is expected to reach USD 50.85 million by 2029, growing at a CAGR of 4.80% during the forecast period (2024-2029).
The COVID-19 pandemic positively impacted the growth of the insulin infusion pump market in the Middle East and Africa. Patients with diabetes infected with SARS-CoV-2 experienced additional stress and increased secretion of hyperglycemic hormones, which resulted in elevated blood glucose, abnormal glucose variability, and diabetic complications. Diabetes and uncontrolled hyperglycemia were risk factors for poor outcomes in patients with COVID-19, including an increased risk of severe illness or death. To avoid complications, the patient's blood glucose level should be maintained at a normal level. The manufacturers of insulin infusion pumps had taken care during COVID-19 to deliver insulin delivery devices to diabetes patients with the help of local governments.
An insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin infusion pumps reduce the large swings in blood glucose levels, lessen pain, and deliver more accurately than injections. The scheduling of meal timings is not required when using pumps, which makes infusion pumps more user-friendly for patients. Insulin therapy is also known as continuous subcutaneous insulin infusion (CSII). It is an efficient and flexible method of insulin delivery.
In the African region, lack of testing facilities and equipment, inadequate number of trained health personnel, poor access to health facilities, and lack of awareness about diabetes are some of the barriers to diabetes testing. Currently, 24 million adults are living with diabetes in Africa. The International Diabetes Federation (IDF) states a 10.5% prevalence of diabetes worldwide. The actual prevalence varies by country and region, and the Middle East and North Africa (MENA) region has one of the world’s highest at 16.2%. Moreover, this is set to increase by 24% by 2045.
Technological advancements in insulin delivery devices have increased for safer and more accurate insulin administration. In 2021, Medtronic launched an Extended infusion set that leverages advanced materials that help reduce insulin preservative loss and maintain insulin flow and stability. The set is compatible with all MiniMed 600 and 700 series insulin pumps. The new tubing connector improves insulin's physical and chemical stability and reliability of infusion site performance and reduces the risk of infusion set occlusion.
Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels. Diabetes poses an emerging healthcare burden across the region.
Owing to the abovementioned factors, the market studied is anticipated to witness growth over the analysis period.
Middle East and African Insulin Infusion Pumps Market Trends
Insulin Pump Device Hold Highest Market Share in current year
Insulin Pump Devices held more than 53% market share in the insulin infusion pumps market in the current year and are expected to grow with a CAGR of around 5% in the market during the forecast period due to the increasing technological advancement and its preference over other traditional methods due to continuous insulin administration.
An insulin pump is a device that delivers insulin continuously or automatically whenever required. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Insulin pump therapy is a well-established insulin administration method for people with type 1 diabetes (T1DM). Pumps are a validated, time-tested therapeutic option in T1DM at all ages, enabling near-physiological insulin delivery in situations where the pancreas does not produce insulin.
There are even pump models with remote controls enabling parents of young children to either suspend or bolus insulin from a distance when the child is playing or eating. The insulin infusion pumps reduce the large swings in blood glucose levels, induce less pain, and deliver more accurately when compared to injections. Continuous subcutaneous insulin infusion (CSII or insulin pumps) and continuous glucose monitoring systems (CGMs) have improved patient care and quality of life and are widely used in the ambulatory setting. Increasingly, this technology is also being used in the hospital setting. These advantages of insulin pumps over the traditional delivery system are expected to boost the market.
The Middle East and African region have witnessed an alarming increase in the prevalence of diabetes; in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Governments in the ME have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have a national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize diabetic complications; therefore, owing to the factors described above, the market's growth is anticipated in the Middle East and Africa.
Egypt is Expected to Dominate the Middle East and Africa Insulin Infusion Pumps Market
Egypt is expected to register a CAGR of over 4% during the forecast period.
Egypt is the ninth country in terms of Diabetes prevalence worldwide. Currently, as per IDF, about 18.4% of the adult population in Egypt has diabetes. Due to the adaptability of new technology and the high prevalence of diabetes, Egypt dominates the market, among other countries. The CGM devices must be used alongside insulin pumps. As the trends show a higher number of diabetic patients moving to CGM for diabetes monitoring, it can be predicted that the number of units of insulin infusion pump devices sold will also follow. The insulin pump has evolved and is more reliable than it was previously. CSII technology has witnessed numerous technological advancements, like integrating continuous glucose monitoring with the pump. Now, insulin pumps can control the algorithm that automatically delivers the insulin after analyzing the blood glucose reading. Type-1 patients require monitored insulin dosages to maintain normal glucose levels, which may generate demand in the coming years.
In Egypt, the social level plays an important role in patients’ access to health care. The number of healthcare centers, hospitals, and pharmacies is very low in rural areas compared to big cities and urban areas. The financial level is a major determinant of people’s access to health care, as the salaries of most of the employees in Egypt are not enough to afford their monthly diabetes supplies. Insulin pumps are neither present nor covered by health insurance in Egypt. For students and school children with type 1 diabetes, the National Health Insurance System covers insulin, and the student pays nothing for NPH, mixed and short-acting insulins, and only 60% of the price of other types of insulin, which are usually not available in the pharmacies of the National Health Insurance System.
However, a growing demand for quality healthcare services in Egypt is spurred by changes, including an increasing aging population and a growing prevalence of lifestyle diseases. The government and private sector are involved in working on healthcare entities and ensuring affordability, access, and quality primary care.
Therefore, owing to the factors above, the growth of the market studied is anticipated in the country.
Middle East and African Insulin Infusion Pumps Industry Overview
The Middle East and African Insulin Infusion Pumps market is consolidated, with few major manufacturers. A few major players, like Becton Dickinson, Medtronics, Ypsomed, and Insulet, dominate the insulin infusion pump devices market.
Middle East and African Insulin Infusion Pumps Market Leaders
Ypsomed
Insulet Corporation
Medtronic PLC
Becton Dickinson
Roche Diabetes Care
*Disclaimer: Major Players sorted in no particular order
Middle East and African Insulin Infusion Pumps Market News
- February 2023: Medtronic PLC announced one-year data from the ADAPT study, the first multi-national randomized controlled study comparing the performance of the MiniMed 780G advanced hybrid closed loop system (AHCL) against multiple daily injections of insulin with an intermittently scanned CGM (isCGM). The study was done in adults (18 years of age and older) who did not meet glycemic targets. The results indicated a TIR increase of 30.2%. At the close of the 6-month study period, all participants on MDI + isCGM crossed over to the MiniMed 780G system. At one year, these significant improvements were reproduced in this cross-over group and sustained in those who started AHCL therapy at the start of the trial.
- March 2022: Ypsomed partnered with CamDiab Ltd, the developer of CamAPS FX, an app to manage glucose levels via insulin pumps using an adaptive, hybrid, closed-loop approach. Patients can then connect the mylife YpsoPump system to the mylife CamAPS FX android mobile application and are enabled algorithm-based insulin delivery support, including bolus from the personal smartphone.
Middle East and Africa Insulin Infusion Pumps Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Component
5.1.1 Insulin Pump
5.1.2 Infusion Set
5.1.3 Reservoir
5.2 Geography
5.2.1 Saudi Arabia
5.2.1.1 Insulin Pump
5.2.1.2 Infusion Set
5.2.1.3 Reservoir
5.2.2 Iran
5.2.2.1 Insulin Pump
5.2.2.2 Infusion Set
5.2.2.3 Reservoir
5.2.3 Egypt
5.2.3.1 Insulin Pump
5.2.3.2 Infusion Set
5.2.3.3 Reservoir
5.2.4 Oman
5.2.4.1 Insulin Pump
5.2.4.2 Infusion Set
5.2.4.3 Reservoir
5.2.5 South Africa
5.2.5.1 Insulin Pump
5.2.5.2 Infusion Set
5.2.5.3 Reservoir
5.2.6 Rest of Middle East and Africa
5.2.6.1 Insulin Pump
5.2.6.2 Infusion Set
5.2.6.3 Reservoir
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Medtronic
7.1.2 Roche
7.1.3 Insulet
7.1.4 Tandem
7.1.5 Ypsomed
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
7.2.1 Insulet
7.2.2 Medtronic
7.2.3 Others
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
Middle East and African Insulin Infusion Pumps Industry Segmentation
An insulin pump is used to deliver insulin to achieve proper blood sugar control and minimize the effects of hypoglycemia. The pump comprises a pump reservoir like an insulin cartridge, a battery-operated pump, and a computer chip that allows the user to control the exact amount of insulin being delivered. The pump is attached to a thin plastic tube (an infusion set) with a soft cannula (or needle) at the end through which insulin passes.
The Middle East and Africa Insulin Infusion Pumps Market is segmented into Components (Insulin Pump, Infusion Set, and Reservoir) and Geography (Saudi Arabia, Iran, Egypt, Oman, and South Africa). The report offers the value (in USD million) and volume (in Units million) for the above segments.
| Component | |
| Insulin Pump | |
| Infusion Set | |
| Reservoir |
| Geography | |||||
| |||||
| |||||
| |||||
| |||||
| |||||
|
Middle East and Africa Insulin Infusion Pumps Market Research Faqs
How big is the Middle East and Africa Insulin Infusion Pumps Market?
The Middle East and Africa Insulin Infusion Pumps Market size is expected to reach USD 40.22 million in 2024 and grow at a CAGR of 4.80% to reach USD 50.85 million by 2029.
What is the current Middle East and Africa Insulin Infusion Pumps Market size?
In 2024, the Middle East and Africa Insulin Infusion Pumps Market size is expected to reach USD 40.22 million.
Who are the key players in Middle East and Africa Insulin Infusion Pumps Market?
Ypsomed, Insulet Corporation, Medtronic PLC, Becton Dickinson and Roche Diabetes Care are the major companies operating in the Middle East and Africa Insulin Infusion Pumps Market.
What years does this Middle East and Africa Insulin Infusion Pumps Market cover, and what was the market size in 2023?
In 2023, the Middle East and Africa Insulin Infusion Pumps Market size was estimated at USD 38.38 million. The report covers the Middle East and Africa Insulin Infusion Pumps Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Middle East and Africa Insulin Infusion Pumps Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Middle East and Africa Insulin Infusion Pumps Industry Report
Statistics for the 2024 Middle East and Africa Insulin Infusion Pumps market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Middle East and Africa Insulin Infusion Pumps analysis includes a market forecast outlook to for 2024 to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
